| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
79,511,000 |
| Market
Cap: |
3.05(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.87 - $39.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avidity Biosciences is a biopharmaceutical company developing a new class of RNA therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. Co.'s lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare monogenic muscle disease. Co. pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
693,245 |
976,647 |
976,647 |
1,216,747 |
| Total Sell Value |
$24,263,469 |
$30,244,321 |
$30,244,321 |
$35,712,938 |
| Total People Sold |
3 |
5 |
5 |
5 |
| Total Sell Transactions |
13 |
24 |
24 |
37 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flanagan W. Michael |
CSTO |
• – – |
2024-01-22 |
4 |
AS |
$10.13 |
$41,827 |
D/D |
(4,129) |
35,871 |
|
159% |
|
| Boyce Sarah |
President and CEO |
• • – |
2024-01-22 |
4 |
AS |
$10.13 |
$51,582 |
D/D |
(5,092) |
44,008 |
|
159% |
|
| Maclean Michael F |
Chief Financial Officer |
• – – |
2024-01-22 |
4 |
AS |
$10.13 |
$16,370 |
D/D |
(1,616) |
16,884 |
|
159% |
|
| Mccarthy Teresa |
Chief Human Resources Officer |
• – – |
2024-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
17,458 |
|
- |
|
| Flanagan W. Michael |
CSTO |
• – – |
2024-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,290 |
|
- |
|
| Boyce Sarah |
President and CEO |
• • – |
2024-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
67,209 |
|
- |
|
| Maclean Michael F |
Chief Financial Officer |
• – – |
2024-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
27,209 |
|
- |
|
| Wilson Troy Edward |
Director |
– • – |
2023-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
550,000 |
300,000 |
|
- |
|
| Wilson Troy Edward |
Director |
– • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(550,000) |
13,711 |
|
- |
|
| Levin Arthur A |
Director |
– • – |
2023-03-15 |
4 |
AS |
$22.01 |
$2,201 |
D/D |
(100) |
19,330 |
|
-57% |
|
| Levin Arthur A |
Director |
– • – |
2023-03-15 |
4 |
OE |
$1.24 |
$124 |
D/D |
100 |
19,430 |
|
- |
|
| Levin Arthur A |
Chief Scientific Officer |
• – – |
2023-02-14 |
4 |
AS |
$23.62 |
$236,567 |
D/D |
(10,000) |
19,330 |
|
-52% |
|
| Levin Arthur A |
Chief Scientific Officer |
• – – |
2023-02-14 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
29,330 |
|
- |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-02-03 |
4 |
AS |
$24.26 |
$78,141 |
D/D |
(3,221) |
53,352 |
|
-50% |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-02-03 |
4 |
OE |
$1.24 |
$3,994 |
D/D |
3,221 |
56,573 |
|
- |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-02-02 |
4 |
AS |
$24.36 |
$1,117,741 |
D/D |
(45,879) |
53,352 |
|
-50% |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-02-02 |
4 |
OE |
$1.24 |
$56,890 |
D/D |
45,879 |
99,231 |
|
- |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-02-01 |
4 |
AS |
$24.27 |
$21,844 |
D/D |
(900) |
53,352 |
|
-51% |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-02-01 |
4 |
OE |
$1.24 |
$1,116 |
D/D |
900 |
54,252 |
|
- |
|
| Maclean Michael F |
Chief Financial Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
18,500 |
21,852 |
|
- |
|
| Flanagan W. Michael |
Chief Technical Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,290 |
|
- |
|
| Levin Arthur A |
Chief Scientific Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
19,330 |
|
- |
|
| Boyce Sarah |
President and CEO |
• • – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
53,352 |
|
- |
|
| Mccarthy Teresa |
Chief Human Resources Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,958 |
|
- |
|
| Levin Arthur A |
Chief Scientific Officer |
• – – |
2023-01-12 |
4 |
AS |
$22.00 |
$220,028 |
D/D |
(10,000) |
1,330 |
|
-47% |
|
89 Records found
|
|
Page 2 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.27 (3.21%) 
